Compare Starbucks Corp (SBUX) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Starbucks Corp vs Spyre Therapeutics Inc. Common Stock — how do they compare? Starbucks Corp trades at $93.36 (market cap $104.88B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Starbucks Corp is far larger — about 13.9× Spyre Therapeutics Inc. Common Stock's market cap, and Starbucks Corp pays a 2.74% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Starbucks Corp for 190 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| SBUX | SYRE | |
|---|---|---|
Market Cap | $104.88B | $7.52B |
Volume | 9,749,448 | 1,441,031 |
Sector | Consumer Cyclical | Health |
52-Week High | $108.55 | $108.92 |
52-Week Low | $79.60 | $22.18 |
Typical Hold Time | 190 Days | 0 Days |
Enterprise Value | $123.70B | $6.52B |
Dividend Yield | 2.74% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SBUX trades at $93.25, up 1.05% on the day, amid a bearish technical signal and mixed fundamentals. Recent earnings show beats in Q1 and Q2 2026 but a miss in Q4 2025, with net income margin at 5.17%. The company is undergoing a strategic reset, closing 250 North American stores to optimize its portfolio, while facing headwinds from labor relations and geopolitical pressures in China.
The stock presents a cautious outlook with a high P/E of 53.18 suggesting premium valuation, yet analyst consensus targets $115.50 imply upside. Key risks include execution of store closures, competitive pressures, and macroeconomic sensitivity. Investor sentiment is divided, balancing restructuring potential against near-term operational challenges.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Starbucks Corp
Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
